Posts Tagged 'pharmaceuticals'

Report says Yaz, Yasmin big money-makers for Bayer

Shannon Pettypiece of Bloomberg Television provides some context for the recent national debates about birth control, pointing out that birth control constitutes “big business for big pharma.”

In a recent report, Ms. Pettypiece observed that Americans spent $5 billion last year for birth control. She said the German corporation Bayer gets about $1.5 billion a year from its drugs Yaz and Yasmin.

See the video here:

http://www.bloomberg.com/video/87718882/

Several studies show that Yaz, Yasmin, continue reading...

Yaz/Beyaz maker Bayer considering “significant” aquisition

Bayer, the German corporation that manufactures birth control pills Yaz, Beyaz and Yasmin, could finance a “significant” acquisition using a combination of debt, equity and its portfolio assets, Bloomberg reports.

Bloomberg cites an interview with Bayer’s Chief Financial Officer Werner Baumann, who said the company would only sell one of its three units “on the merits of its own strategic assessment.”

“You will not find us in a situation where we say we want to buy this, therefore we have to sell ...

continue reading...

Journalist: Women should be aware of Yaz/Beyaz risks

A recent piece in the magazine “Ms.” by journalist Holly Grigg-Spall urges more women to educate themselves about potential health risks concerning the birth control pills Yaz and Beyaz, manufactured by German corporation Bayer.

Ms. Grigg-Spall points out that Yaz became the most popular birth control pill in the U.S. soon after its release in 2006, as the result of a marketing campaign that the federal Food and Drug Administration subsequently ruled to be misleading. The FDA requested that Bayer run ...

continue reading...

New pharmaceuticals boost profits for Bayer

German corporation Bayer will rely on commercialization of its new pharmaceutical products to bolster its profits in the year ahead.

A recent report by the corporate giant trumpets its sales in the past year, stating they rose by 4.1 percent in 2011 to $48.2 million. The report specifically mentions Bayer’s HeathCare subgroup, responsible for pharmaceutical products, as contributing to the profitability.

“One of our strengths continues to be our well-stocked development pipeline in pharmaceuticals,” Bayer CEO Dr. Marijn Dekkers said. Several times, ...

continue reading...